NCT00899808

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2006

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2006

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

May 9, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 12, 2009

Completed
Last Updated

May 29, 2015

Status Verified

May 1, 2015

Enrollment Period

Same day

First QC Date

May 9, 2009

Last Update Submit

May 27, 2015

Conditions

Hematopoietic/Lymphoid CancerUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specificunspecified childhood solid tumor, protocol specifichematopoietic/lymphoid cancer

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients undergoing radiation therapy for malignant disease will be eligible for these studies. Initially we will focus on specific disease sites, such as breast, prostate and lung, but ultimately we will expand this to include any disease site. Patients who met standard criteria for radiation therapy but ultimately did not receive radiation therapy will be used as a control arm if needed.

DISEASE CHARACTERISTICS: * Diagnosis of cancer * Undergoing radiation therapy for malignant disease PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Rutgers Cancer Institute of New Jersey - Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08903, United States

Location

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Bruce G. Haffty, MD

    Rutgers Cancer Institute of New Jersey- Robert Wood Johnson Medical School

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2009

First Posted

May 12, 2009

Study Start

May 1, 2006

Primary Completion

May 1, 2006

Last Updated

May 29, 2015

Record last verified: 2015-05

Locations

US(1)